Citric acid

Juna Announces Its Much-Anticipated Detox Drops January 2022

Retrieved on: 
Friday, January 14, 2022 - 6:58pm

The beauty of Detox Drops, like all products from Juna, lies in its superlative quality natural ingredients, which are science-backed and completely safe.

Key Points: 
  • The beauty of Detox Drops, like all products from Juna, lies in its superlative quality natural ingredients, which are science-backed and completely safe.
  • The active ingredients in Detox Drops include chlorophyllin from white mulberry, sodium, copper, organic flax/coconut-derived glycerin, mint essential oil, lemon essential oil, citric acid, distilled purified water, and other organic extracts.
  • Juna is launching its Detox Drops at an attractive inaugural price.
  • As the research-backed key ingredient in Detox Drops, chlorophyll is the superhero agent that amplifies the body's oxygen supply for cellular regeneration, boosts metabolism, stimulates the organs, clears impurities, and clarifies the mind and body, shared the founders.

Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 2b Ifenprodil Chronic Cough Study

Retrieved on: 
Friday, January 14, 2022 - 1:15pm

The U.S. FDA also requested standard genotoxicity testing be completed prior to beginning the Phase 2b study, which the Company estimates will take approximately 90 days to complete.

Key Points: 
  • The U.S. FDA also requested standard genotoxicity testing be completed prior to beginning the Phase 2b study, which the Company estimates will take approximately 90 days to complete.
  • The Company filed the pre-IND meeting request to seek guidance in the event the Company decides to move forward with a chronic cough Phase 2b study in the U.S. On September 20, 2021, the Company reported positive trending interim data from the chronic cough part of its 20-patient proof-of-concept Phase 2 idiopathic pulmonary fibrosis (IPF) and chronic cough study being conducted in Australia and New Zealand.
  • In Algernons pre-clinical animal cough study, Ifenprodil showed both a dramatic reduction in cough count and a delay in cough onset when compared to vehicle controls in a well-accepted acute cough in-vivo animal study.
  • Gefapixant, Mercks lead phase 3 trial drug for chronic cough, was also tested in the study.

Gelesis®, the Maker of Plenity® for Weight Management, Will Debut as a Publicly Traded Company Following the Closing of Its Business Combination with Capstar

Retrieved on: 
Thursday, January 13, 2022 - 11:41pm

Gelesis, the maker of Plenity, an FDA-cleared weight management approach, announced today the completion of its business combination with Capstar Special Purpose Acquisition Corp. (NYSE: CPSR) (Capstar).

Key Points: 
  • Gelesis, the maker of Plenity, an FDA-cleared weight management approach, announced today the completion of its business combination with Capstar Special Purpose Acquisition Corp. (NYSE: CPSR) (Capstar).
  • The transaction generated approximately $105 million in gross proceeds, which will be mainly used to support the broad launch of Plenity.
  • Approximately 71 million Americans gained weight during the pandemic and 51% of all Americans wanted to lose weight this past year1.
  • Plenity is transforming weight management with a clinically proven approach inspired by raw vegetables.

Phexxi Access to Expand under New Government Guidance Stating Insurers Must Cover FDA-approved Contraceptives with No Out-of-Pocket Costs to Women

Retrieved on: 
Wednesday, January 12, 2022 - 11:00am

"We anticipate that millions more women will be able to access Phexxi at no cost without overly burdensome denials or being forced to try other products first."

Key Points: 
  • "We anticipate that millions more women will be able to access Phexxi at no cost without overly burdensome denials or being forced to try other products first."
  • The Company's first FDA-approved product, Phexxi (lactic acid, citric acid and potassium bitartrate), is ahormone-free, on-demand prescription contraceptive vaginal gel.
  • Forward-looking statements are statements other than historical facts and relate to future events or circumstances and the Company's future performance.
  • The Company does not undertake any duty to update any forward-looking statement except as required by law.

25 MILLION FOOT PEELS SOLD IN 25 YEARS

Retrieved on: 
Tuesday, January 11, 2022 - 11:00am

Baby Foot Exfoliation Foot Peel for Men - Mint Scented - Remove the ruggedness with the foot exfoliation treatment designed specifically for men's feet.

Key Points: 
  • Baby Foot Exfoliation Foot Peel for Men - Mint Scented - Remove the ruggedness with the foot exfoliation treatment designed specifically for men's feet.
  • Baby Foot Moisturizing Foot Mask - Unscented Intense foot hydration treatment powered with collagen, hyaluronic acid and 14 natural extracts.
  • Baby Foot Spa Bundle: Original Peel, 2 Foot Soaks & Foot Scrub The perfect one-week treatment experience containing 1 Original Baby Foot Exfoliation Foot Peel, 2 Foot Soak Packets and 1 tube of Foot Scrub for an optimum spa experience in your own home.
  • "As the original creator of the foot peel category, Baby Foot is proud to say that we have sold 25 million-foot peels in 25 years," says Ms. Gibbons.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Citrix Systems, Inc. (CTXS)

Retrieved on: 
Monday, January 10, 2022 - 3:00pm

On April 29, 2021, before the market opened, Citrix announced that customers did not transition from shorter-duration, on-premise licenses to long-term cloud accounts as expected.

Key Points: 
  • On April 29, 2021, before the market opened, Citrix announced that customers did not transition from shorter-duration, on-premise licenses to long-term cloud accounts as expected.
  • On this news, Citrixs stock fell $10.49, or 7.6%, to close at $128.02 per share on April 29, 2021, thereby injuring investors.
  • Then, on July 29, 2021, Citrix reported that the transition to cloud was not as successful as the Company had led investors to believe.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

Evofem Biosciences to Present at H.C. Wainwright BioConnect Conference

Retrieved on: 
Tuesday, January 4, 2022 - 12:00pm

SAN DIEGO, Jan. 4, 2022 /PRNewswire/ --Evofem Biosciences, Inc., (NASDAQ:EVFM) today announced that the Company will present and host one-on-one meetings at the H.C. Wainwright BioConnect Virtual Conference being held from January 10 13, 2022.

Key Points: 
  • SAN DIEGO, Jan. 4, 2022 /PRNewswire/ --Evofem Biosciences, Inc., (NASDAQ:EVFM) today announced that the Company will present and host one-on-one meetings at the H.C. Wainwright BioConnect Virtual Conference being held from January 10 13, 2022.
  • The Company's presentation will be available for on demand listening beginning at 7:00am ET on Monday, January 10, 2022 through the H.C. Wainwright BioConnect conference portal and via https://evofem.investorroom.com/HCWJan22 for 90 days.
  • To request a one-on-one meeting with Evofem during the conference, please contact your H.C. Wainwright representative or email ir@evofem.com .
  • Phexxiis a registered trademark of Evofem Biosciences, Inc.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Citrix Systems, Inc. (CTXS)

Retrieved on: 
Tuesday, December 28, 2021 - 6:00pm

On April 29, 2021, before the market opened, Citrix announced that customers did not transition from shorter-duration, on-premise licenses to long-term cloud accounts as expected.

Key Points: 
  • On April 29, 2021, before the market opened, Citrix announced that customers did not transition from shorter-duration, on-premise licenses to long-term cloud accounts as expected.
  • On this news, Citrixs stock fell $10.49, or 7.6%, to close at $128.02 per share on April 29, 2021, thereby injuring investors.
  • Then, on July 29, 2021, Citrix reported that the transition to cloud was not as successful as the Company had led investors to believe.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Citrix Systems, Inc. (CTXS)

Retrieved on: 
Thursday, December 16, 2021 - 4:00pm

On April 29, 2021, before the market opened, Citrix announced that customers did not transition from shorter-duration, on-premise licenses to long-term cloud accounts as expected.

Key Points: 
  • On April 29, 2021, before the market opened, Citrix announced that customers did not transition from shorter-duration, on-premise licenses to long-term cloud accounts as expected.
  • On this news, Citrixs stock fell $10.49, or 7.6%, to close at $128.02 per share on April 29, 2021, thereby injuring investors.
  • Then, on July 29, 2021, Citrix reported that the transition to cloud was not as successful as the Company had led investors to believe.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

Global White Biotechnology Market (2021 to 2026) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 16, 2021 - 4:04pm

As a result, white biotechnology finds extensive applications across various industries, including bioenergy, textile, construction, chemical, food and beverage and pharmaceutical.

Key Points: 
  • As a result, white biotechnology finds extensive applications across various industries, including bioenergy, textile, construction, chemical, food and beverage and pharmaceutical.
  • Key Questions Answered in This Report:
    How has the global white biotechnology market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global white biotechnology market?
  • What is the structure of the global white biotechnology market and who are the key players?